LCTX

Lineage Cell Therapeutics, Inc.

0.98 USD
-0.07 (-6.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lineage Cell Therapeutics, Inc. stock is down -12.51% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48.48% of the previous 32 May’s closed higher than April. 100% of analysts rate it a buy.

About Lineage Cell Therapeutics, Inc.

OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, are in clinical trials to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.